


Entera Bio Ltd. (ENTX)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001638097

Entera Bio Ltd.	
ENTX; healthcare	
Grade	D A B C D E fourth fifth of 371 graded peers percentile 65.4; sampling error 2.5 points; lower is stronger
Rank	243 of 371
Profitability	C percentile 54.8
Solvency	C percentile 49.8
Growth and financing	C percentile 54.8
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$16.0M
Standard universe	outside revenue above \$1M and assets above \$10M
Warnings	degenerate inputs not computable: distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 27, 2026 196 days before the rescans; latest periodic filing 10-Q received Aug 7, 2026
Last close	\$2.51 2026-10-08; market equity \$434.6M
Price used in grade	None



D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: E from Apr 21, 2025, D from Apr 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm. Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2: Currently, most protein therapies are administered via frequent intravenous, subcutaneous or

intramuscular injections.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 54.8						
Gross profitability		0.0%	32.2%	95.8	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(32.1%)	(6.6%)	13.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			annual revenue must exceed \$100,000
Solvency, sleeve percentile 49.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(20.27)	(0.31)	73.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		6.94x	2.96x	25.9	839	2025-12-31
Growth and financing, sleeve percentile 54.8						
Revenue growth, three-year compound		(32.1%)	10.0%	91.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		6.8%	2.1%	37.1	704	2025-12-31
Net share issuance, one year		2.6%	2.5%	35.4	634	2026-03-23


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
238	Integra Lifesciences Holdings Corp. (IART)	64.1	D	
239	Alpha Teknova, Inc. (TKNO)	64.3	D	
240	Arvinas, Inc. (ARVN)	64.6	D	short runway, fortress balance sheet
241	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet
242	Fulgent Genetics, Inc. (FLGT)	65.1	D	short runway
243	Entera Bio Ltd. (ENTX) <	65.4	D	degenerate inputs
244	Dentsply Sirona Inc. (XRAY)	65.7	D	
245	InspireMD, Inc. (NSPR)	65.9	D	dilution, short runway, distress
246	Angiodynamics Inc. (ANGO)	66.2	D	fortress balance sheet
247	AIM ImmunoTech Inc. (AIM)	66.5	D	late filer, degenerate inputs, distress
248	Exagen Inc. (XGN)	66.8	D	dilution, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	53.6%	8.0%	78
Distance from 52-week high	(36.2%)	(31.4%)	41
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(1.7%)	(1.0%)	48
Book value to price	0.02	0.28	14
Sales to price	0.00	0.31	1
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.22	(0.14)	78

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$11.3M
Operating cash flow, four quarters	-\$10.9M
Months of runway	12.5
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$1.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$0	2025-12-31	2026-03-27	10-K	0001178913-26-001797
2	assets	us-gaap:Assets	\$16.0M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
3	net income	us-gaap:NetIncomeLoss	-\$11.4M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$7.4M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
5	assets	us-gaap:Assets	\$9.4M	2024-12-31	2026-03-27	10-K	0001178913-26-001797
6	revenue	us-gaap:Revenues	\$42,000	2025-12-31	2026-03-27	10-K	0001178913-26-001797
7	current assets	us-gaap:AssetsCurrent	\$15.3M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
8	current liabilities	us-gaap:LiabilitiesCurrent	\$2.2M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$125.4M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
10	operating income	us-gaap:OperatingIncomeLoss	-\$11.5M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
11	book equity	us-gaap:StockholdersEquity	\$13.1M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
12	liabilities	us-gaap:Liabilities	\$2.9M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
13	revenue	us-gaap:Revenues	\$181,000	2024-12-31	2026-03-27	10-K	0001178913-26-001797
14	revenue	us-gaap:Revenues	\$0	2023-12-31	2025-03-28	10-K	0001178913-25-001112
15	revenue	us-gaap:Revenues	\$134,000	2022-12-31	2024-03-08	10-K	0001178913-24-000881
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$107,000	2025-12-31	2026-03-27	10-K	0001178913-26-001797
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$6.8M	2024-12-31	2026-03-27	10-K	0001178913-26-001797
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3,000	2024-12-31	2026-03-27	10-K	0001178913-26-001797
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$7.3M	2023-12-31	2025-03-28	10-K	0001178913-25-001112
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$17,000	2023-12-31	2025-03-28	10-K	0001178913-25-001112
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$12.5M	2022-12-31	2024-03-08	10-K	0001178913-24-000881
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$47,000	2022-12-31	2024-03-08	10-K	0001178913-24-000881
23	depreciation amortization	us-gaap:Depreciation	\$30,000	2025-12-31	2026-03-27	10-K	0001178913-26-001797
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests	\$11.4M	2025-12-31	2026-03-27	10-K	0001178913-26-001797
25	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-27	10-K	0001178913-26-001797
26	current assets	us-gaap:AssetsCurrent	\$9.0M	2024-12-31	2026-03-27	10-K	0001178913-26-001797
27	current liabilities	us-gaap:LiabilitiesCurrent	\$1.2M	2024-12-31	2026-03-27	10-K	0001178913-26-001797
28	assets	us-gaap:Assets	\$11.8M	2023-12-31	2025-03-28	10-K	0001178913-25-001112
29	assets	us-gaap:Assets	\$13.1M	2022-12-31	2024-03-08	10-K	0001178913-24-000881
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	46,622,239	2026-03-23	2026-03-27	10-K	0001178913-26-001797
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	45,420,676	2025-03-20	2025-03-28	10-K	0001178913-25-001112